Genomic & Biopharma NewsElectronic Sun Sentinel: Gene analysis lab moves to Deerfield Beach
|ORB Company News, 2016-12-02 21:24:27|
NICE nod for Takeda’s Adcetris in advanced stage CTCL
Takeda has announced the NICE recommendation of Adcetris for advanced cutaneous T-cell lymphoma.
|PharmaTimes, 2019-03-22 13:14:20|
Celgene and Exscientia ink three year AI drug discovery collaboration
Exscientia has announced a three-year drug discovery AI collaboration with Celgene.
|PharmaTimes, 2019-03-22 13:13:17|
CCG report shows increase in emergency readmissions
NHS Digital has published emergency readmissions statistics for first time in five years.
|PharmaTimes, 2019-03-22 13:11:03|
CRISPR diagnostic maker Sherlock Biosciences says the game’s afoot with $35M launch
Sherlock Biosciences is launching with $35 million and a two-pronged approach to improving the current state of diagnostics, with the goal of creating new tools that “reach further out, where testing isn’t being done today, but should be."
|Fierce Biotech, 2019-03-22 11:53:08|
Using the Mastermind strategy in brain research
The brain is a complex organ, and researching medicine to treat brain disorders is equally if not more complex. Elizabeth (Liesbeth) de Lange, Professor of Predictive Pharmacology, calls for a structured approach.
|News Medical Life Sciences, 2019-03-22 11:47:04|
Conatus and Novartis suffer another midphase NASH flop
Conatus Pharmaceuticals’ emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease drug fail to beat placebo in NASH patients, wiping another 50% off Conatus’ stock price.
|Fierce Biotech, 2019-03-22 10:22:34|
Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County.
|ORB Company News, 2016-12-02 15:35:33|
Aspiring doctors seek advanced training in addiction medicine
The U.S. Surgeon General’s office estimates that more than 20 million people have a substance use disorder. Meanwhile, the nation’s drug overdose crisis shows no sign of slowing.
|News Medical Life Sciences, 2019-03-22 10:13:53|
FiercePharmaAsia—Aducanumab Alzheimer’s flop; Keytruda’s Chinese market; Samsung BioLogics probe
Biogen and Eisai's Alzheimer's candidate aducanumab didn't make it through phase 3 testing; analysts argue Keytruda could see blockbuster sales in China thanks to its stellar clinical profile; South Korean prosecutors raid Korea Exchange offices in Samsung BioLogics probe; and more.
|Fierce Pharma, 2019-03-22 09:56:52|
1 day after aducanumab disaster, Eisai kick-starts backup Alzheimer’s drug trial
Albert Einstein is often attributed as saying: “The definition of insanity is doing the same thing over and over again, but expecting different results.” He likely didn’t actually say this, but regardless of its origins, this witticism comes sharply into focus when you read Eisai’s press release about starting new trials for BAN2401.
|Fierce Biotech, 2019-03-22 09:31:17|